653 results on '"Kim, Kang Mo"'
Search Results
152. Long‐term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country
153. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid–enhanced MRI
154. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up
155. Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
156. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection
157. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin
158. IDDF2018-ABS-0168 Utility of FDG-PET/CT in pre-transplantation workup of the potential liver recipient with hepatocellular carcinoma
159. IDDF2018-ABS-0235 Reappraisal of the accuracy of diagnostic criteria for spontaneous bacterial peritonitis in cirrhotic patients with or without hepatocellular carcinoma: a preliminary result
160. Methionine Adenosyltransferase 1: A Proteomic Surrogate Marker of Early Hepatocellular Carcinoma in Cirrhotic Patients
161. Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study
162. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
163. Association between non-alcoholic fatty liver disease and cancer incidence rate
164. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin
165. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B
166. Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
167. Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice
168. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells
169. Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid–enhanced MR Imaging and Dynamic CT
170. TGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC
171. Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids
172. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes
173. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
174. An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys)
175. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area
176. Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma
177. Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis
178. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
179. Response to Letter Regarding Article, “Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis: A Registry-Based Matched Case–Control Study”
180. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model
181. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization
182. Prognostic Nomograms for Prediction of Recurrence and Survival After Curative Liver Resection for Hepatocellular Carcinoma
183. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance
184. Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met induction
185. Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma
186. Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection
187. Retraction notice to: Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma [J. Hepatol. 2014;60:1212–1218]
188. Sa1557 - Normal Values of Liver Stiffness as Measured by Transient Elastography: Pooled Individual Participant Data Meta-Analysis from 26 Studies and 14,883 Participants
189. Clinical characteristics and initial treatment patterns of patients with HCC in Korea: A multi-center real-world database analysis from the LINK research network.
190. Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection
191. Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis
192. "A Case of the Effective Treatment of HCC with Bile Duct Invasion and Portal Vein Thrombosis
193. Gα12 gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation
194. RETRACTED: Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma
195. Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma
196. microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression
197. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment
198. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
199. Prevalence Analysis of de novo Hepatic Steatosis Following Pylorus-Preserving Pancreaticoduodenectomy
200. Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.